Pregene Signs an Exclusive License Agreement with CellPoint to Develop and Commercialize PRG-1801 for the Treatment of R/R Multiple Myeloma
Shots:
- Pregene to receive ~$21.78M upfront along with near-term consideration & is also eligible to receive additional development, a commercial milestone along with royalty
- CellPoint will be responsible for the development and commercialization of the anti-BCMA CAR-T therapy in the US & EU. Pregene will also provide translational and lentivirus manufacturing services to be reimbursed by Cellpoint
- PRG-1801 is an anti-BCMA CAR-T cell therapy & has shown strong signs of efficacy and an excellent safety profile in its initial investigator-initiated trial and P-I/II clinical trials. The therapy is also being studied for the treatment of autoimmune diseases
Ref: PR Newswire | Image: Crunchbase
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
